Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.42 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.42 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.42 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | BHMT | Q93088 | 1/20 | 0.37 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.37 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 2/20 | 0.36 |
| ▸ | GABRD | O14764 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33273 | 1.00 | FFAR3 (0.43) | FFAR3GRIK1GRIA4GRIK3GRIK5 | |
| SCHEMBL16359636 | 1.00 | FFAR3 (0.43) | FFAR3GRIK1GRIA4GRIK3GRIK5 | |
| SCHEMBL13146871 | 0.81 | FFAR3 (0.46) | FFAR3GRIK1GRIA4GRIK3GRIK5 | |
| SCHEMBL14771690 | 0.80 | GRIK1 (0.38) | FFAR3GRIK1GRIA4GRIK3GRIK5 | |
| SCHEMBL21345146 | 0.80 | GRIK1 (0.38) | FFAR3GRIK1GRIA4GRIK3GRIK5 | |
| SCHEMBL16021873 | 0.80 | TDP1 (0.43) | FFAR3GRIK1GRIA4GRIK3GRIK5 | |
| Aspartic Acid SCHEMBL7781260 | 0.80 | GRIK1 (0.57) | FFAR3GRIK1GRIA4GRIK3GRIK5 | |
| SCHEMBL16024166 | 0.80 | ALDH1A1 (0.43) | FFAR3GRIK1GRIA4GRIK3GRIK5 | |
| Aspartic Acid SCHEMBL135731 | 0.80 | GRIK1 (0.57) | FFAR3GRIK1GRIA4GRIK3GRIK5 | |
| SCHEMBL10068031 | 0.80 | GRIK1 (0.38) | FFAR3GRIK1GRIA4GRIK3GRIK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11066425-B1 | Oxo-substituted compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-07-20 | — | — | US | disclosed |
| WO-2019173602-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2019-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066425-B1 | Oxo-substituted compound | CYP51A1, OXA1L, O60361 | FFAR3 4629/4885GRIK1 2762/4885GRIA4 3920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.